Related Experiment Videos
Elastin: mutational spectrum in supravalvular aortic stenosis
K Metcalfe1, A K Rucka, L Smoot
1University Department of Medical Genetics and Regional Genetics Service, St Mary's Hospital, Manchester, UK.
European Journal of Human Genetics : EJHG
|February 15, 2001
Summary
Supravalvular aortic stenosis (SVAS) is a congenital aorta narrowing caused by elastin gene mutations. This study identified various mutations, including novel missense types, in 35% of patients, aiding understanding of SVAS pathology.
Area of Science:
- Genetics
- Cardiovascular Medicine
- Molecular Biology
Background:
- Supravalvular aortic stenosis (SVAS) is a congenital narrowing of the ascending aorta.
- It can be sporadic, autosomal dominant, or part of Williams syndrome.
- SVAS is linked to mutations in the elastin gene (ELN) on chromosome 7q11.23.
Purpose of the Study:
- To investigate the spectrum of elastin gene mutations in patients with SVAS and normal karyotypes.
- To elucidate the pathogenic mechanisms of point mutations in SVAS.
- To identify molecular lesions for potential preventative treatments.
Main Methods:
- Screening of 100 patients with diagnosed SVAS and normal karyotypes for elastin gene mutations.
- Analysis of mutation types including nonsense, frameshift, translation initiation, splice site, and missense mutations.
Main Results:
- Mutations in the elastin gene were detected in 35% (35 out of 100) of patients.
- Identified mutations included nonsense, frameshift, translation initiation, and splice site mutations.
- Four novel missense mutations, the first associated with SVAS, were identified.
Conclusions:
- The study describes the mutation spectrum in familial and sporadic SVAS.
- It provides insights into the mutational mechanisms underlying SVAS.
- Identifying these molecular lesions is crucial for developing future preventative strategies for SVAS.